文献速递肝病

抑制ATGL通过损害PPARα信号促进亲水性胆汁酸组成减轻小鼠MASH

Inhibition of ATGL alleviates MASH via impaired PPARα signalling that favours hydrophilic bile acid composition in mice.
PubMed 文献 · J Hepatol · 2024-09-30

研究在小鼠MASH模型中探讨ATGL抑制剂atglistatin的作用,发现其改善肝酶、肝脂质含量和组织学肝损伤,机制涉及减弱PPARα信号、促进亲水性胆汁酸合成、干扰膳食脂质吸收;人源抑制剂NG-497在类器官和细胞中重现类似机制,但atglistatin对人ATGL无效限制其临床适用性。

要点

  • ATGL抑制剂atglistatin改善小鼠MASH的肝酶、肝脂质含量和组织学肝损伤。
  • 机制为减弱PPARα信号,促进亲水性胆汁酸合成并干扰膳食脂质吸收。
  • 人ATGL抑制剂NG-497在人回肠类器官和细胞中重现类似治疗机制。

核心结论

  • 抑制ATGL减弱PPARα信号,促成亲水性胆汁酸组成,干扰膳食脂质吸收并改善代谢紊乱。
  • 用人ATGL抑制剂NG-497验证为MASLD提供了新的治疗视角。
  • atglistatin对人ATGL缺乏效力,限制其临床适用性。

研究设计与样本

  • 链脲佐菌素注射的雄性小鼠喂高脂饮食诱导MASH,比较ATGL抑制剂atglistatin(ATGLi)组与对照组,采用肝脏组织学、脂质组学、代谢组学、16s rRNA和RNA测序分析。
  • 分析人回肠类器官、HepG2细胞和Caco2细胞经人ATGL抑制剂NG-497处理,以及HepG2 ATGL敲低细胞、凝胶迁移和荧光素酶试验以探讨机制。
  • 在低甲硫氨酸胆碱缺乏小鼠模型中验证ATGLi对脂肪性肝炎和纤维化的益处。

主要发现

  • ATGLi改善血清肝酶、肝脏脂质含量和组织学肝损伤。
  • ATGLi减弱PPARα信号,促进亲水性胆汁酸合成,伴Cyp7a1、Cyp27a1、Cyp2c70表达增加和Cyp8b1表达减少。
  • 肠道Cd36和Abca1降低、Abcg5升高,与肝脏中含亚油酸等多不饱和脂肪酸的三酰甘油种类水平降低以及肝脏和血浆胆固醇水平降低一致。
  • NG-497处理的人回肠类器官中观察到与PPARα信号和肠道脂质转运相关的类似基因表达变化。
  • HepG2 ATGL敲低细胞显示PPARα靶基因表达降低和亲水性胆汁酸合成相关基因上调,与ATGL抑制剂存在时PPARα结合减少和荧光素酶活性降低一致。

局限性

  • atglistatin的缺点之一是对人ATGL缺乏效力,从而限制其临床适用性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Adipose triglyceride lipase (ATGL) is an attractive therapeutic target in insulin resistance and metabolic dysfunction-associated steatotic liver disease (MASLD). This study investigated the effects of pharmacological ATGL inhibition on the development of metabolic dysfunction-associated steatohepatitis (MASH) and fibrosis in mice. METHODS: Streptozotocin-injected male mice were fed a high-fat diet to induce MASH. Mice receiving the ATGL inhibitor atglistatin (ATGLi) were compared to controls using liver histology, lipidomics, metabolomics, 16s rRNA, and RNA sequencing. Human ileal organoids, HepG2 cells, and Caco2 cells treated with the human ATGL inhibitor NG-497, HepG2 ATGL knockdown cells, gel-shift, and luciferase assays were analysed for mechanistic insights. We validated the benefits of ATGLi on steatohepatitis and fibrosis in a low-methionine choline-deficient mouse model. RESULTS: ATGLi improved serum liver enzymes, hepatic lipid content, and histological liver injury. Mechanistically, ATGLi attenuated PPARα signalling, favouring hydrophilic bile acid (BA) synthesis with increased Cyp7a1, Cyp27a1, Cyp2c70, and reduced Cyp8b1 expression. Additionally, reduced intestinal Cd36 and Abca1, along with increased Abcg5 expression, were consistent with reduced levels of hepatic triacylglycerol species containing polyunsaturated fatty acids, like linoleic acid, as well as reduced cholesterol levels in the liver and plasma. Similar changes in gene expression associated with PPARα signalling and intestinal lipid transport were observed in ileal organoids treated with NG-497. Furthermore, HepG2 ATGL knockdown cells revealed reduced expression of PPARα target genes and upregulation of genes involved in hydrophilic BA synthesis, consistent with reduced PPARα binding and luciferase activity in the presence of the ATGL inhibitors. CONCLUSIONS: Inhibition of ATGL attenuates PPARα signalling, translating into hydrophilic BA composition, interfering with dietary lipid absorption, and improving metabolic disturbances. Validation with NG-497 opens a new therapeutic perspective for MASLD. IMPACT AND IMPLICATIONS: Despite the recent approval of drugs novel mechanistic insights and pathophysiology-oriented therapeutic options for MASLD (metabolic dysfunction-associated steatotic liver disease) are still urgently needed. Herein, we show that pharmacological inhibition of ATGL, the key enzyme in lipid hydrolysis, using atglistatin (ATGLi), improves MASH (metabolic dysfunction-associated steatohepatitis), fibrosis, and key features of metabolic dysfunction in mouse models of MASH and liver fibrosis. Mechanistically, we demonstrated that attenuation of PPARα signalling in the liver and gut favours hydrophilic bile acid composition, ultimately interfering with dietary lipid absorption. One of the drawbacks of ATGLi is its lack of efficacy against human ATGL, thus limiting its clinical applicability. Against this backdrop, we could show that ATGL inhibition using the human inhibitor NG-497 in human primary ileum-derived organoids, Caco2 cells, and HepG2 cells translated into therapeutic mechanisms similar to ATGLi. Collectively, these findings reveal a possible new avenue for MASLD treatment.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Dixon ED, Claudel T, Nardo AD, et al. Inhibition of ATGL alleviates MASH via impaired PPARα signalling that favours hydrophilic bile acid composition in mice. J Hepatol. 2024. PMID: 39357546. doi:10.1016/j.jhep.2024.09.037

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。